[Longitudinal study of the metabolic syndrome after kidney transplantation].
BACKGROUND
The occurence of the metabolic syndrome (MS) between the renal receptors is one of the major complications after transplantation and is associated with an increased risk of graft failure and high rates of obesity and diabetes new appearance.


OBJECTIVE
This study aims to investigate the prevalence and risk factors associated with the development of the MS and to evaluate the association between the same with the allograft dysfunction.


METHODS
The samples consisted of 138 renal transplant patients, 83 men and 55 women, kidney transplant, which was attended by over five years for the transplant consultation. Were analyzed as potential risk factors for MS: age, sex, body mass index (BMI), weight, hypertension, diabetes, LDL, HDL, triglycerides in serum and immunosuppressive therapy (cyclosporine, tacrolimus, mycophenolate mofetil), was also assessed the prevalence of acute rejection episodes and renal function.


RESULTS
The prevalence of MS was 39.85 %. As statistically significant risk factors were obtained the BMI, overweight, HDL cholesterol levels, triglycerides and LDL as well as hypertension and diabetes. There were high rates of acute rejection and differences in story to the glomerular filtration rate.


CONCLUSIONS
There is a high prevalence of the MS that severely compromised renal function and graft survival in renal transplant patients, it is very important the control and strict monitoring of all risk factors identified.
Universidad de Granada. Facultad de Ciencias de la Salud. Departamento de Enfermería.. rafaelfernandez@ugr.es.
Rafael
R
Fernández Castillo
Servicio de Nefrología Unidad de Hemodiálisis. Hospital Universitario Virgen de las Nieves. Granada. España.. ruthfg@telefonica.net.
Ruth
R
Fernández Gallegos
Servicio de Nefrología Unidad de Hemodiálisis. Hospital Universitario Virgen de las Nieves. Granada. España.. falitos@gmail.com.
Gloria María
GM
Zaragoza Fernández
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D016030:Kidney Transplantation; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000453:epidemiology / Q000209:etiology*; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology*; D015995:Prevalence; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D007166:Immunosuppressive Agents; D008055:Lipids